Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14053-

  Wu, Chuanfeng ^a   Hong, So Gun ^a   Winkler, Thomas ^a   Spencer, David M ^b   Jares, Alexander ^a   Ichwan, Brian ^a   Nicolae, Alina ^c   Guo, Vicky ^a   Larochelle, Andre ^a   Dunbar, Cynthia E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Arcadis US   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CASPASE 9; DNA; ELONGATION FACTOR 1ALPHA; RIMIDUCID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CPG ISLAND; CYTOMEGALOVIRUS; DNA METHYLATION; DOWN REGULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INDUCED PLURIPOTENT STEM CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; STEM CELL TRANSPLANTATION; SUICIDE GENE; SUICIDE GENE THERAPY; SUICIDE TRANSGENE; TERATOMA;

EID: 85015639659     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.53     Document Type: Article

References (48)

1. 1 Takahashi, K, Yamanaka, S, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
2. 2 Takahashi, K, Tanabe, K, Ohnuki, M, Narita, M, Ichisaka, T, Tomoda, K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
3. 3 de Peppo, GM, Marolt, D, State of the art in stem cell research: human embryonic stem cells, induced pluripotent stem cells, and transdifferentiation. J Blood Transfus, 2012, 2012, 317632.
4. 4 Hanna, J, Wernig, M, Markoulaki, S, Sun, CW, Meissner, A, Cassady, JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318 (2007), 1920–1923.
5. 5 Lu, TY, Lin, B, Kim, J, Sullivan, M, Tobita, K, Salama, G, et al. Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells. Nat Commun, 4, 2013, 2307.
6. 6 Hong, SG, Winkler, T, Wu, C, Guo, V, Pittaluga, S, Nicolae, A, et al. Path to the clinic: assessment of iPSC-based cell therapies in vivo in a nonhuman primate model. Cell Rep 7 (2014), 1298–1309.
7. 7 Kuroda, T, Yasuda, S, Sato, Y, Tumorigenicity studies for human pluripotent stem cell-derived products. Biol Pharm Bull 36 (2013), 189–192.
8. 8 Ben-David, U, Benvenisty, N, The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 11 (2011), 268–277.
9. 9 Blum, B, Benvenisty, N, The tumorigenicity of human embryonic stem cells. Adv Cancer Res 100 (2008), 133–158.
10. 10 Ciceri, F, Bonini, C, Gallo-Stampino, C, Bordignon, C, Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy 7 (2005), 144–149.
11. 11 Barese, CN, Krouse, AE, Metzger, ME, King, CA, Traversari, C, Marini, FC, et al. Thymidine kinase suicide gene-mediated ganciclovir ablation of autologous gene-modified rhesus hematopoiesis. Mol Ther 20 (2012), 1932–1943.
12. 12 Bonini, C, Bondanza, A, Perna, SK, Kaneko, S, Traversari, C, Ciceri, F, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 15 (2007), 1248–1252.
13. 13 Dachs, GU, Hunt, MA, Syddall, S, Singleton, DC, Patterson, AV, Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 14 (2009), 4517–4545.
14. 14 Mailly, L, Leboeuf, C, Tiberghien, P, Baumert, T, Robinet, E, Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. Curr Opin Investig Drugs 11 (2010), 559–570.
15. 15 Schuldiner, M, Itskovitz-Eldor, J, Benvenisty, N, Selective ablation of human embryonic stem cells expressing a “suicide” gene. Stem Cells 21 (2003), 257–265.
16. 16 Jung, J, Hackett, NR, Pergolizzi, RG, Pierre-Destine, L, Krause, A, Crystal, RG, Ablation of tumor-derived stem cells transplanted to the central nervous system by genetic modification of embryonic stem cells with a suicide gene. Hum Gene Ther 18 (2007), 1182–1192.
17. 17 Cheng, F, Ke, Q, Chen, F, Cai, B, Gao, Y, Ye, C, et al. Protecting against wayward human induced pluripotent stem cells with a suicide gene. Biomaterials 33 (2012), 3195–3204.
18. 18 Chen, F, Cai, B, Gao, Y, Yuan, X, Cheng, F, Wang, T, et al. Suicide gene-mediated ablation of tumor-initiating mouse pluripotent stem cells. Biomaterials 34 (2013), 1701–1711.
19. 19 Zhong, B, Watts, KL, Gori, JL, Wohlfahrt, ME, Enssle, J, Adair, JE, et al. Safeguarding nonhuman primate iPS cells with suicide genes. Mol Ther 19 (2011), 1667–1675.
20. 20 Bonini, C, Ferrari, G, Verzeletti, S, Servida, P, Zappone, E, Ruggieri, L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1997), 1719–1724.
21. 21 Ciceri, F, Bonini, C, Stanghellini, MT, Bondanza, A, Traversari, C, Salomoni, M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 10 (2009), 489–500.
22. 22 Fareed, MU, Moolten, FL, Suicide gene transduction sensitizes murine embryonic and human mesenchymal stem cells to ablation on demand– a fail-safe protection against cellular misbehavior. Gene Ther 9 (2002), 955–962.
23. 23 Menzel, O, Birraux, J, Wildhaber, BE, Jond, C, Lasne, F, Habre, W, et al. Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates. Mol Ther 17 (2009), 1754–1760.
24. 24 Lim, TT, Geisen, C, Hesse, M, Fleischmann, BK, Zimmermann, K, Pfeifer, A, Lentiviral vector mediated thymidine kinase expression in pluripotent stem cells enables removal of tumorigenic cells. PLoS ONE, 8, 2013, e70543.
25. 25 Berger, C, Flowers, ME, Warren, EH, Riddell, SR, Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107 (2006), 2294–2302.
26. 26 Garin, MI, Garrett, E, Tiberghien, P, Apperley, JF, Chalmers, D, Melo, JV, et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97 (2001), 122–129.
27. 27 Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365 (2011), 1673–1683.
28. 28 Spencer, DM, Wandless, TJ, Schreiber, SL, Crabtree, GR, Controlling signal transduction with synthetic ligands. Science 262 (1993), 1019–1024.
29. 29 Fan, L, Freeman, KW, Khan, T, Pham, E, Spencer, DM, Improved artificial death switches based on caspases and FADD. Hum Gene Ther 10 (1999), 2273–2285.
30. 30 Straathof, KC, Pulè, MA, Yotnda, P, Dotti, G, Vanin, EF, Brenner, MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 105 (2005), 4247–4254.
31. 31 Kiuru, M, Boyer, JL, O'Connor, TP, Crystal, RG, Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell 4 (2009), 289–300.
32. 32 Lawrenz, B, Schiller, H, Willbold, E, Ruediger, M, Muhs, A, Esser, S, Highly sensitive biosafety model for stem-cell-derived grafts. Cytotherapy 6 (2004), 212–222.
33. 33 Fujikawa, T, Oh, SH, Pi, L, Hatch, HM, Shupe, T, Petersen, BE, Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol 166 (2005), 1781–1791.
34. 34 Darabi, R, Gehlbach, K, Bachoo, RM, Kamath, S, Osawa, M, Kamm, KE, et al. Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat Med 14 (2008), 134–143.
35. 35 Amariglio, N, Hirshberg, A, Scheithauer, BW, Cohen, Y, Loewenthal, R, Trakhtenbrot, L, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med, 6, 2009, e1000029.
36. 36 Hong, SG, Dunbar, CE, Winkler, T, Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells. Mol Ther 21 (2013), 272–281.
37. 37 Hotta, A, Cheung, AY, Farra, N, Vijayaragavan, K, Séguin, CA, Draper, JS, et al. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods 6 (2009), 370–376.
38. 38 Yang, X, Boehm, JS, Yang, X, Salehi-Ashtiani, K, Hao, T, Shen, Y, et al. A public genome-scale lentiviral expression library of human ORFs. Nat Methods 8 (2011), 659–661.
39. 39 Mao, G, Marotta, F, Yu, J, Zhou, L, Yu, Y, Wang, L, et al. DNA context and promoter activity affect gene expression in lentiviral vectors. Acta Biomed 79 (2008), 192–196.
40. 40 Doerfler, W, Hoeveler, A, Weisshaar, B, Dobrzanski, P, Knebel, D, Langner, KD, et al. Promoter inactivation or inhibition by sequence-specific methylation and mechanisms of reactivation. Cell Biophys 15 (1989), 21–27.
41. 41 Duan, B, Cheng, L, Gao, Y, Yin, FX, Su, GH, Shen, QY, et al. Silencing of fat-1 transgene expression in sheep may result from hypermethylation of its driven cytomegalovirus (CMV) promoter. Theriogenology 78 (2012), 793–802.
42. 42 Choi, KH, Basma, H, Singh, J, Cheng, PW, Activation of CMV promoter-controlled glycosyltransferase and beta -galactosidase glycogenes by butyrate, tricostatin A, and 5-aza-2’-deoxycytidine. Glycoconj J 22 (2005), 63–69.
43. 43 Škalamera, D, Dahmer, M, Purdon, AS, Wilson, BM, Ranall, MV, Blumenthal, A, et al. Generation of a genome scale lentiviral vector library for EF1a promoter-driven expression of human ORFs and identification of human genes affecting viral titer. PLoS ONE, 7, 2012, e51733.
44. 44 Cesana, D, Ranzani, M, Volpin, M, Bartholomae, C, Duros, C, Artus, A, et al. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther 22 (2014), 774–785.
45. 45 Ou, W, Li, P, Reiser, J, Targeting of herpes simplex virus 1 thymidine kinase gene sequences into the OCT4 locus of human induced pluripotent stem cells. PLoS ONE, 8, 2013, e81131.
46. 46 Pfaff, N, Lachmann, N, Ackermann, M, Kohlscheen, S, Brendel, C, Maetzig, T, et al. A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells 31 (2013), 488–499.
47. 47 Wu, C, Jares, A, Winkler, T, Xie, J, Metais, JY, Dunbar, CE, High efficiency restriction enzyme-free linear amplification-mediated polymerase chain reaction approach for tracking lentiviral integration sites does not abrogate retrieval bias. Hum Gene Ther 24 (2013), 38–47.
48. 48 Sommer, CA, Stadtfeld, M, Murphy, GJ, Hochedlinger, K, Kotton, DN, Mostoslavsky, G, Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 27 (2009), 543–549.